SLC29A1 and kidney disorder: SLC29A1, along with SLC29A2, are inhibited by nitrobenzylthioinosine (NBMPR), as well as dipryridamole, a vasodilator and blood thinner; dilazep, a vasodilator used in cardiopathy and renal disorders; and draflazine, a vasodilator (Wright and Lee, 2019).